About this trial
Neonatal patients with congenital heart defects (CHD) have changing physiology in the context of transitional period. Patients with CHD are at risk of low perfusion status or abnormal pulmonary blood flow. Near infrared spectroscopy has been used in neonatal intensive care units (NICU) to measure end-organ perfusion. The investigator plan on monitoring newborns with CHD admitted to the NICU with NIRS and echocardiography during the first week of life and correlate measures of perfusion from Dopplers to cerebral and renal NIRS.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
All newborns with tetralogy of fallot, truncus arteriosus, D-transposition of great arteries, PS, AS, coarctation of the aorta, DILV, AVC, DORV, HLHS, TA and PAIVS consecutively admitted at our institution (Montreal Children's Hospital) neonatal intensive care unit (NICU) from January 2018 to January 2020.
Trial design
Cohort
Retrospective
Treatments tested in this trial
NIRS evaluation
DeviceNIRS will be used for measurement of cerebral and renal saturation.
Treatment groups
Trial outcomes
Primary outcomes
Correlation between cerebral saturation and ACA doppler
Correlation between aortic doppler and renal NIRS measures
Secondary outcomes
Correlation between LV performance by STE and Csat and Rsat by NIRs
Sponsors and contacts
Click on the lead sponsor to view all of their trials.